The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells

Cho, Min-Ji; Kim, Myeong Joo; Kim, Ki-Jeong; Choi, Young Wook; Lee, Sang-Jin; Whang, Young Mi; Chang, In Ho

doi:10.1016/j.bbrc.2018.12.097

Cited by 15 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 With regard to histological characteristics, nearly 90% of BCs are urothelial carcinoma, of which approximately 75%-85% are classified as non-muscle invasive BC (NMIBC) and the rest MIBC. 2 At present, treatment options for BC include surgery, 3 radiotherapy, chemotherapy, 4 immunotherapy, 5 and recently developed immunocheckpoint inhibitors. 6 In general, the American Joint Committee on Cancer TNM-staging system is used to guide prognosis and management options for BC patients.…”

Section: Introductionmentioning

confidence: 99%

Extracellular Matrix–Related Six-lncRNA Signature as a Novel Prognostic Biomarker for Bladder Cancer

Qing¹,

Gu²,

Liu³

et al. 2020

OTT

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Extracellular Matrix–Related Six-lncRNA Signature as a Novel Prognostic Biomarker for Bladder Cancer

Qing¹,

Gu²,

Liu³

et al. 2020

OTT

View full text Add to dashboard Cite

“…Cho et al produced recombinant BCGexpressing proteins that inhibit AMPs and lead to low survival of BC cells in vitro due to increased BCG internalization and cytokine secretion. 57…”

Section: Recombinant Bcgsmentioning

confidence: 99%

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update

Guallar-Garrido

Julián

2020

ITT

129

View full text Add to dashboard Cite

Physicians treating patients affected by nonmuscle-invasive bladder cancer (NMIBC) have been in shock during the last six years since manufacturing restrictions on the production of the first-option medicine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), have resulted in worldwide shortages. This shortage of BCG has led to a rethinking of the established treatment guidelines for the rationing of the administration of BCG. Some possible schedule modifications consist of a decrease in the length of maintenance treatment, a reduction in the dose of BCG in intravesical instillations or the use of different BCG substrains. All these strategies have been considered valuable in times of BCG shortage. In addition, the lack of availability of BCG has also led to the general recognition of the need to find new treatment options for these patients so that they are not dependent on a single treatment. Few alternatives are committed to definitively replacing BCG intravesical instillations, but several options are being evaluated to improve its efficacy or to combine it with other chemotherapeutic or immunotherapeutic options that can also improve its effect. In this article, we review the current state of the treatment with BCG in terms of all of the aforementioned aspects.

show abstract

“…- Cancer vaccines , novel biological drugs such as BCG vaccines have been evaluated to elicit an immune response and modulate side effects using recombinant BCG strains able to stimulate Th1 immune cells as well as induce cytokine release (Cho et al, 2019 ; Rodriguez et al, 2019 ).…”

Section: Modern Anticancer Therapymentioning

confidence: 99%

New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis

et al. 2020

View full text Add to dashboard Cite

About 70% of bladder cancers (BCs) are diagnosed as non-muscle-invasive BCs (NMIBCs), while the remaining are muscle-invasive BCs (MIBCs). The European Association of Urology (EAU) guidelines stratify NMIBCs into low, intermediate, and high risk for treatment options. Low-risk NMIBCs undergo only the transurethral resection of the bladder (TURB), whereas for intermediate-risk and high-risk NMIBCs, the transurethral resection of the bladder (TURB) with or without Bacillus Calmette-Guérin (BCG) immune or chemotherapy is the standard treatment. A minority of NMIBCs show unfavorable prognosis. High-risk NMIBCs have a high rate of disease recurrence and/or progression to muscle-invasive tumor and BCG treatment failure. The heterogeneous nature of NMIBCs poses challenges for clinical decision-making. In 2020, the EAU made some changes to NMIBCs BCG failure definitions and treatment options, highlighting the need for reliable molecular markers for improving the predictive accuracy of currently available risk tables. Nowadays, next-generation sequencing (NGS) has revolutionized the study of cancer biology, providing diagnostic, prognostic, and therapy response biomarkers in support of precision medicine. Integration of NGS with other cutting-edge technologies might help to decipher also bladder tumor surrounding aspects such as immune system, stromal component, microbiome, and urobiome; altogether, this might impact the clinical outcomes of NMBICs especially in the BCG responsiveness. This review focuses on NMIBCs with unfavorable prognoses, providing molecular prognostic factors from tumor immune and stromal cells, and the perspective of urobiome and microbiome profiling on therapy response. We provide information on the cornerstone of immunotherapy and new promising bladder-preserving treatments and ongoing clinical trials for BCG-unresponsive NMIBCs.

show abstract

The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells

Cited by 15 publications

References 15 publications

<p>Extracellular Matrix–Related Six-lncRNA Signature as a Novel Prognostic Biomarker for Bladder Cancer</p>

<p>Extracellular Matrix–Related Six-lncRNA Signature as a Novel Prognostic Biomarker for Bladder Cancer</p>

<p>Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update</p>

New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis

Contact Info

Product

Resources

About